Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Gliadel Wafer and O6-Benzylguanine in Treating Patients With Recurrent Glioblastoma Multiforme

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Duke University
ClinicalTrials.gov Identifier:
NCT00362921
First received: August 10, 2006
Last updated: July 9, 2014
Last verified: February 2013